NEW YORK (GenomeWeb) – OpGen after the close of the market Wednesday reported a 128 percent increase in its first quarter revenues.

For the three months ended March 31, the Gaithersburg, Maryland-based infectious disease testing and bioinformatics firm reported revenues of $1.1 million, up from $472,200 in the first quarter of 2015. The rise is attributable to sales of AdvanDx diagnostic products and CLIA laboratory services provided using the Acuitas multi-drug resistant organisms testing suite, OpGen Chairman and CEO Evan Jones said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.